Overall rate of adverse events · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in overall rate of adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Headache · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL probably leads to higher headache compared with placebo (moderate certainty).
1 finding from 1 review
Insomnia · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL may leads to higher insomnia compared with placebo (low certainty).
1 finding from 1 review
Nausea · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL may leads to higher nausea compared with placebo (low certainty).
1 finding from 1 review
Diarrhoea · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in diarrhoea compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in discontinuation due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Incidence of SAD (SIGH‐SAD score ≥ 20) ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether bright white light therapy changes incidence of SAD (SIGH‐SAD score ≥ 20) ( compared with no light therapy (very low certainty).
1 finding from 1 review
Incidence of SAD (SIGH‐SAD score ≥ 20) ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether bright white light therapy changes incidence of SAD (SIGH‐SAD score ≥ 20) ( compared with infrared light therapy (very low certainty).
1 finding from 1 review
Incidence of severe SAD (SIGH‐SAD‐SR (≥ 40)) ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether bright white light therapy changes incidence of severe SAD (SIGH‐SAD‐SR (≥ 40)) ( compared with infrared light therapy (very low certainty).
1 finding from 1 review
Overall discontinuation ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether bright white light therapy changes overall discontinuation ( compared with infrared light therapy (very low certainty).
1 finding from 1 review
Incidence of severe SAD (SIGH‐SAD‐SR (≥ 40)) ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether bright white light therapy changes incidence of severe SAD (SIGH‐SAD‐SR (≥ 40)) ( compared with no light therapy (very low certainty).
1 finding from 1 review
Overall discontinuation ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether bright white light therapy changes overall discontinuation ( compared with no light therapy (very low certainty).
1 finding from 1 review
Incidence of SAD (SIGH‐SAD score ≥ 20) ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether infrared light therapy changes incidence of SAD (SIGH‐SAD score ≥ 20) ( compared with no light therapy (very low certainty).
1 finding from 1 review
Incidence of severe SAD (SIGH‐SAD‐SR (≥ 40)) ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether infrared light therapy changes incidence of severe SAD (SIGH‐SAD‐SR (≥ 40)) ( compared with no light therapy (very low certainty).
1 finding from 1 review
Overall discontinuation ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether infrared light therapy changes overall discontinuation ( compared with no light therapy (very low certainty).
1 finding from 1 review
Incidence of SAD (SIGH‐SAD score ≥ 20) ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether light therapy changes incidence of SAD (SIGH‐SAD score ≥ 20) ( compared with no light therapy (very low certainty).
1 finding from 1 review
Incidence of severe SAD (SIGH‐SAD‐SR (≥ 40)) ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether light therapy changes incidence of severe SAD (SIGH‐SAD‐SR (≥ 40)) ( compared with no light therapy (very low certainty).
1 finding from 1 review
Overall discontinuation ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether light therapy changes overall discontinuation ( compared with no light therapy (very low certainty).
1 finding from 1 review
Incidence of SAD (IDS‐SR > 20) · adults with a history of SAD but without depressive symptoms when treatment started
It is very uncertain whether mindfulness‐based cognitive therapy (MBCT) changes incidence of SAD (IDS‐SR > 20) compared with treatment (very low certainty).
1 finding from 1 review
Severity of SAD ( · adults with a history of SAD but without depressive symptoms when treatment started
1 finding from 1 review